OnKure Therapeutics Email Format
Pharmaceutical ManufacturingColorado, United States11-50 Employees
OnKure Therapeutics is a Boulder, Colorado–based pharmaceutical company focused on precision oncology, aiming to discover and develop medicines that target biologically validated drivers of cancer. It concentrates on PI3Kα inhibitors for breast cancer and other solid tumors with PIK3CA mutations, pursuing a next-generation approach to targeted therapy. In 2024, OnKure merged with Reneo Pharmaceuticals, becoming a publicly listed company and positioning itself within the clinical-stage biopharma landscape. The organization operates as a small to mid-sized player in the pharmaceutical manufacturing industry, developing targeted therapies that address cancers driven by specific genetic alterations. Its work centers on delivering precision medicines for breast cancer and related solid tumors, seeking to translate targeted biology into clinical candidates.